MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome.
about
Biomarkers for Primary Sjögren's SyndromeThe clinical relevance of animal models in Sjögren's syndrome: the interferon signature from mouse to manAdvancing Point-of-Care (PoC) Testing Using Human Saliva as Liquid BiopsyTear cathepsin S as a candidate biomarker for Sjögren's syndrome.Gene Expression Profiling in Peripheral Blood Cells and Synovial Membranes of Patients with Psoriatic ArthritisType I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndromeSjögren's syndrome-associated microRNAs in CD14(+) monocytes unveils targeted TGFβ signaling.Identification of definitive serum biomarkers associated with disease activity in primary Sjögren's syndromeGenome-wide DNA methylation analysis in multiple tissues in primary Sjögren's syndrome reveals regulatory effects at interferon-induced genes.SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome.A review of salivary gland histopathology in primary Sjögren's syndrome with a focus on its potential as a clinical trials biomarker.Safety of treatments for primary Sjögren's syndrome.Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options.Innate immunity in Sjögren's syndrome.Lateral flow immunoassay with upconverting nanoparticle-based detection for indirect measurement of interferon response by the level of MxA.H1N1 vaccination in Sjögren's syndrome triggers polyclonal B cell activation and promotes autoantibody production.Gene Expression Analysis before and after Treatment with Adalimumab in Patients with Ankylosing Spondylitis Identifies Molecular Pathways Associated with Response to Therapy.Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors?Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren's Syndrome.Immune Response to Rotavirus and Gluten Sensitivity.MicroRNA Expression Profiling in Behçet's Disease.Gene Expression Profiling in Behcet's Disease Indicates an Autoimmune Component in the Pathogenesis of the Disease and Opens New Avenues for Targeted Therapy.Type 1 interferon-inducible gene expression in QuantiFERON Gold TB-positive uveitis: A tool to stratify a high versus low risk of active tuberculosis?
P2860
Q26781381-EE5E28F0-0894-463E-AE42-C819645CA074Q26825196-B750A680-BE7F-4E10-9634-022C701A65B1Q33455416-AA4636BD-FB2F-4377-B58F-EFA272D66C0AQ33831656-E8834527-8983-40C2-A540-5127E0771E83Q35667354-7E60F578-1ACA-4175-9855-058059260624Q36042432-367E74C1-36F4-4288-925C-34779522DEE0Q36247683-3B197EF0-A707-4054-A770-C8B9E1D2964CQ36859599-103F1111-B3EC-4DE1-B9C9-815413A536C0Q36867243-112EF2A4-DDFF-40B7-A77B-EA090789CE52Q36903959-B9DE7152-01C2-473C-B315-1D110F59F8CFQ37398914-7F83B1E8-7C4B-4D98-8BEB-E9500BDB5B36Q37587370-B10CEA46-0AE6-4B68-AB12-44E2AE13E8A9Q38512291-FF9A3358-487A-4037-907D-1E3B1493E52BQ38711144-8F45FC5C-3E62-42CE-A5A1-8C679E8CC2B3Q38867891-44C48A87-5232-477A-99A3-97D9A1BC1247Q39232871-3D8FBA2F-4E92-47FD-9EB0-3B71D4E17B1CQ40537863-24AF02F6-E6D7-43C1-AFE6-A82EEB696B81Q41912227-F288BB92-7ABC-4F25-9A96-E03B25013A69Q42081086-44CED53D-0F3D-4D20-B2FB-3792A734A4BDQ49299269-C0DDD103-8E0F-4FE9-B50B-848D62D0C6AFQ50670959-FB6C2238-1098-45DF-AEF2-B606FFCA1F38Q54988424-5739913E-B939-42F6-B179-62DB59583542Q55101372-587215E0-5F09-469E-ACDA-7BB3C9A8B2F1Q55140887-B51A43EB-D1F1-4103-8085-BBE6B2E099B7Q58601433-F090D109-CCC2-4F9C-A2B1-ACB1757B2BA9
P2860
MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
MxA as a clinically applicable ...... in primary Sjogren's syndrome.
@ast
MxA as a clinically applicable ...... in primary Sjogren's syndrome.
@en
type
label
MxA as a clinically applicable ...... in primary Sjogren's syndrome.
@ast
MxA as a clinically applicable ...... in primary Sjogren's syndrome.
@en
prefLabel
MxA as a clinically applicable ...... in primary Sjogren's syndrome.
@ast
MxA as a clinically applicable ...... in primary Sjogren's syndrome.
@en
P2093
P2860
P1476
MxA as a clinically applicable ...... in primary Sjogren's syndrome
@en
P2093
Cornelia G van Helden-Meeuwsen
Hemmo A Drexhage
Joop P van de Merwe
Kim Heezen
Marjan A Versnel
Naomi I Maria
Paul L van Daele
Virgil A S H Dalm
Zana Brkic
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-202552
P407
P577
2013-07-06T00:00:00Z